European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases

Chris P Twine*, Stavros K Kakkos, Victor Aboyans, Iris Baumgartner, Christian-Alexander Behrendt, Sergi Bellmunt-Montoya, Bernd Jilma, Joakim Nordanstig, Athanasios Sarazis, J. A. Reekers, Petar Zlatanovic, George Antoniou, Gert Jan de Borst, Frederico Goncalves, N. Chakfé, Raphael Coscas, Nuno Dias, Robert J Hinchliffe, P. Kolh, J. S. LindholtBarend M E Mees, Timothy Resch, Santi Trimarchi, Riikka Tulamo, Frank Vermassen, Anders Wanhainen, Igor Koncar, Robert Fitridge, M Matsagas, Marco Valgimigli

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

Original languageEnglish
Pages (from-to)627-689
Number of pages63
JournalEuropean Journal of Vascular and Endovascular Surgery
Issue number5
Early online date3 Apr 2023
Publication statusPublished - 19 May 2023

Bibliographical note

Funding Information:
Members of the Guideline Writing Committee (GWC) were selected by the guideline chairs and ESVS Guideline Steering Committee to represent clinician groups involved in antithrombotic therapy decision making for patients with vascular disease. This included representation from the disciplines of angiology, phlebology, cardiology, clinical pharmacology, interventional radiology, vascular medicine, and vascular surgery ( Appendix A ). Members of the GWC have provided disclosure statements regarding relationships that might be perceived as conflicts of interest. These are available from ESVS headquarters ( ). Members of the GWC received no financial support from any pharmaceutical, device, or industry body to develop these guidelines. Videoconference software support was funded by the ESVS. The ESVS Guideline Steering Committee was responsible for undertaking the review process and reviewed the document at each round. The final version was checked and approved by the GWC and ESVS Guideline Steering Committee.

Funding Information:
The authors would like to thank: Mr Graeme Ambler, Consultant vascular surgeon at Addenbrooke's Hospital Cambridge, for performing a network meta-analysis comparing clopidogrel with aspirin and rivaroxaban for patients with stable PAD for this guideline. 186 Professor Byung-Boong Lee, Centre for the Lymphoedema and Vascular Malformations, George Washington University, Washington, DC, USA, for advice for section 6 Congenital vascular malformation. Dr Dominick McCabe, member of the ESVS carotid guideline writing committee Trinity College, Dublin, for text from the updated ESVS carotid guideline which helped harmonise recommendations in 4.1 Atherosclerotic carotid artery disease and 4.2 Atherosclerotic vertebral artery disease. Professor Stephan Moll, Professor of Medicine at UNC School of Medicine, for consenting to the reproduction of a table for section 4.11.4 Thrombophilia (publisher permission also obtained). 277 Professor Ross Naylor, chair of the ESVS carotid guidelines, for help harmonising sections 4.1 Atherosclerotic carotid artery disease and 4.2 Atherosclerotic vertebral artery disease with the updated ESVS carotid guideline, which was developed in parallel with this guideline. Dr Marlene Stewart, managing editor of Cochrane Vascular for co-ordinating the update of the Cochrane Review “Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts”. 36 Dr Kitty Wong, foundation doctor at North Bristol NHS trust, for performing two meta-analyses for this guideline in association with Dr Petar Zlatanovic. 34, 35

Cite this